PMC8685211_01
Sarcoma component (x100).
fonc-11-603591-g001.jpg
PMC8685211_01_fonc-11-603591-g001.jpg
f1
Pelvic MRI on April 1, 2019. Coronal view showing an anterior abdominal wall metastasis after niraparib administration for 20 months.
fonc-11-603591-g002.jpg
PMC8685211_01_fonc-11-603591-g002.jpg
f2
On April 1, 2019, 20 months after the secondary cytoreductive surgery, MRI showed an anterior abdominal wall metastasis, as a locally isolated lesion of 2.4 cmx0.9 cm ( Figure 2 ).
PMC8685211_02
Pelvic MRI on September 3, 2018. Coronal view showing no new lesions after niraparib administration for one year.
fonc-11-603591-g003.jpg
PMC8685211_02_fonc-11-603591-g003.jpg
f3
MRI showed no disease progression at 13 months after the second surgery ( Figure 3 ).
Pelvic MRI on June 5, 2020. No recurrence was found.
fonc-11-603591-g004.jpg
PMC8685211_02_fonc-11-603591-g004.jpg
f4
The patient has been on niraparib plus bevacizumab maintenance therapy since April 2020, and the latest CT showed no sign of recurrence ( Figure 4 ).